Cerebriu has raised a two million euros seed round to support R&D, international clinical trials, and initial implementation at hospitals. Investors include KMD Venture, Crista Galli Ventures and Vaekstfonden – The Danish Growth Fund, and a few business angels, acknowledging Cerebriu’ value proposition of simplifying diagnostics and patient journey in radiology by applying AI technology. Initial use case is acute diagnostics, e.g. in connection with stroke.
Cerebriu’s Apollo Smart Protocol solution simplifies radiology and patient journeys and thus saves valuable time for both physicians and patients, while at the same time improving quality and outcomes. The solution integrates seamlessly with existing clinical protocols and workflows, but filters data automatically and immediately while the patient is still in the scanner and thus critical clinical decisions can be accelerated. This approach is unique among the many radiology AI solutions available.
“The Danish Growth Fund sees great potential in Cerebriu’s AI technology and the application within radiology, which will improve and accelerate patient diagnosing based on imaging. We are very pleased to add an important healthcare AI start-up like Cerebriu to our portfolio”, says Lene Gerlach, Investment Manager at VF Venture – the department of equity investments in Vaekstfonden . “We strongly support the use and scale up of digital health solutions that can revolutionize patient treatment, achieving higher standards of health and well-being. Digital innovation is mandatory in the healthcare industry, as it provides opportunities to accelerate the progress of attaining the UN Sustainable Development Goals, especially SDG3 Good Health and Well-being. We believe that Cerebriu will play an important role in improving the healthcare industry with digital intelligence.”
Ready to deploy first commercial solutions
Having CE-marked the first product Apollo for Brain, hospitals can now implement the solution and harvest the obvious benefits of simplifying the patient journey through MRI scanning and subsequent diagnosis. Initial focus is acute stroke MRI examinations
“As a radiologist myself, I am drawn to Cerebriu as its technology acts as a software upgrade in MRI, resulting in faster scan times and increased patient throughput. This means better patient experiences and improved workflow efficiency. I am looking forward to being part of the Cerebriu journey.” Dr. Fiona Pathiraja (MD), Managing Partner at Crista Galli Ventures, London, U.K.
Globally more than two billion USD have been invested in radiology AI companies thus far. Most radiology AI startups focus on x-ray and CT, whereas Cerebriu focuses on MRI. This modality is the fastest growing and since it is the most complex, the potential benefits of simplifying the patient journey are just much more compelling.
“KMD Venture A/S is always looking for innovative deep tech startups. Cerebriu is addressing real health tech problems with state-of-the-art technology and we are very much looking forward to being part of this exciting journey. ”, Niklas Marschall, CEO KMD Venture.
“We’re humbled with the task at hand and greatly appreciate the solid backing from our institutional investors, focusing now on getting into production supporting clinical workflows around acute stroke and other acute findings, made possible with this investment supporting our R&D and more importantly commercialization in this rapidly growing space”, Robert Lauritzen, CEO Cerebriu